In this podcast, UROONCO RCC chief editor Dr. Carmen Mir interviews Prof. Nizar Tannir from the University of Texas, MD Anderson Cancer Center, USA, on the long-term follow-up data from the phase 3 CheckMate 214 trial: Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC). Prof. Tannir summarises the history and stability of the Checkmate 214 trial results over the last 8 years, before discussing the latest data from his presentation at ASCO GU24 in San Francisco.For more details on this trail, you can read the abstract on the UROONCO Kidney Cancer educational platform.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
3ª PARTE | 17 DIC 2025 | EL PARTIDAZO DE COPE
01 Jan 1970
El Partidazo de COPE
13:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
10:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
13:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana